EPS for Selecta Biosciences, Inc. (SELB) Expected At $-0.72

July 14, 2018 - By Kristin Houston

Analysts expect Selecta Biosciences, Inc. (NASDAQ:SELB) to report $-0.72 EPS on August, 10.They anticipate $0.13 EPS change or 15.29 % from last quarter’s $-0.85 EPS. After having $-0.71 EPS previously, Selecta Biosciences, Inc.’s analysts see 1.41 % EPS growth. The stock increased 5.54% or $0.7 during the last trading session, reaching $13.33. About 209,563 shares traded or 11.23% up from the average. Selecta Biosciences, Inc. (NASDAQ:SELB) has declined 8.28% since July 14, 2017 and is downtrending. It has underperformed by 20.85% the S&P500.

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company has market cap of $297.92 million. The Company’s lead product candidate is SEL-212, which is in phase I/II clinical trials for the treatment of refractory and chronic tophaceous gout. It currently has negative earnings.

More important recent Selecta Biosciences, Inc. (NASDAQ:SELB) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018, also Benzinga.com published article titled: “Janney: 4 Reasons Why Selecta Biosciences Is ‘Significantly Undervalued'”, Seekingalpha.com published: “Selecta Biosciences’ SEL-212 shows positive effect in mid-stage gout study” on June 15, 2018. More interesting news about Selecta Biosciences, Inc. (NASDAQ:SELB) was released by: Globenewswire.com and their article: “Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout …” with publication date: June 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.